Updated April 2026

Ozempic in the UK:
Your Complete Guide

NHS availability, private prescription costs, eligibility criteria, side effects, dosage and everything else you need to know about semaglutide.

Key facts about Ozempic

  • Active ingredient: Semaglutide
  • Manufacturer: Novo Nordisk
  • UK licence: Type 2 diabetes (MHRA-approved)
  • Administration: Once-weekly subcutaneous injection
  • NHS availability: Available for type 2 diabetes management
  • Private cost: Approximately £150–£250 per month

What is Ozempic?

Ozempic is a prescription medicine containing semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. Manufactured by Novo Nordisk, it was originally developed and licensed for the treatment of type 2 diabetes in adults. In the UK, Ozempic received its marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) and has been available on the NHS for diabetes management since 2019.

Semaglutide works by mimicking a natural hormone produced in the gut after eating. It stimulates insulin secretion when blood sugar levels are elevated, reduces the amount of glucose produced by the liver, and slows gastric emptying, which helps create a prolonged feeling of fullness after meals.

Although Ozempic is not specifically licensed for weight management in the UK (that indication belongs to Wegovy, which contains a higher dose of semaglutide), many patients experience significant weight loss as a secondary benefit. This has led to considerable public interest and, at times, supply pressures.

NHS availability and eligibility

Ozempic is available on the NHS as a treatment for type 2 diabetes in adults. According to NICE guidelines (NG28), GLP-1 receptor agonists such as semaglutide may be considered when other glucose-lowering treatments have not achieved adequate glycaemic control.

NHS eligibility criteria for Ozempic

To be prescribed Ozempic on the NHS, patients typically need to meet several criteria:

Your GP or diabetes specialist will assess whether Ozempic is appropriate based on your individual clinical circumstances. Some Clinical Commissioning Groups (now Integrated Care Boards) may have additional local prescribing criteria.

Important: Ozempic is not licensed for weight management alone in the UK. If you are seeking a GLP-1 medication specifically for weight loss, your clinician may consider Wegovy or Mounjaro instead.

Private prescriptions: costs and providers

If you do not meet NHS eligibility criteria or prefer not to wait for an NHS referral, Ozempic can be obtained through private healthcare providers. Several regulated online clinics and high street pharmacies now offer private prescriptions for semaglutide.

Typical private costs

Dose Approximate monthly cost Notes
0.25 mg (starting dose) £150–£180 First 4 weeks
0.5 mg (maintenance) £170–£220 Weeks 5–8
1 mg (standard) £200–£250 Most common maintenance dose
2 mg (maximum) £220–£280 If additional control needed

Prices vary between providers and may include or exclude the cost of a clinical consultation. Always check that any online pharmacy you use is registered with the General Pharmaceutical Council (GPhC) and that the prescriber is registered with the General Medical Council (GMC).

How Ozempic is used

Ozempic is administered as a subcutaneous injection once a week, on the same day each week. The injection is given using a pre-filled pen device into the abdomen, thigh or upper arm. Most patients find the injection straightforward and relatively painless.

Dosage schedule

Treatment follows a gradual dose-escalation approach to minimise gastrointestinal side effects:

  1. Weeks 1–4: 0.25 mg once weekly (initiation dose, not therapeutic)
  2. Weeks 5–8: 0.5 mg once weekly
  3. Week 9 onwards: 1 mg once weekly (standard maintenance dose)
  4. If needed: Dose may be increased to 2 mg once weekly after at least 8 weeks on 1 mg

The starting dose of 0.25 mg is intended to allow your body to adjust to the medication and is not a therapeutic dose. It is important not to skip the escalation steps, as doing so increases the likelihood of side effects.

Side effects of Ozempic

Like all medicines, Ozempic can cause side effects, although not everybody experiences them. The most frequently reported side effects are gastrointestinal in nature and typically improve as the body adjusts to the medication.

Very common side effects (more than 1 in 10 people)

Common side effects (up to 1 in 10 people)

Uncommon but serious side effects

For a more detailed overview of side effects across all GLP-1 medications, see our GLP-1 side effects guide.

Who should not take Ozempic?

Ozempic is not suitable for everyone. According to the Summary of Product Characteristics (SmPC) and BNF guidance, it should not be used in the following circumstances:

Caution is also advised in patients with a history of pancreatitis, severe gastrointestinal disease, or diabetic retinopathy. Your prescriber will conduct a thorough assessment before initiating treatment.

Ozempic vs Wegovy vs Mounjaro

It is helpful to understand how Ozempic compares with other GLP-1 medications available in the UK. While all three share a similar mechanism of action, they differ in their licensed indications, dosing and clinical outcomes.

Feature Ozempic Wegovy Mounjaro
Active ingredient Semaglutide Semaglutide Tirzepatide
UK licence Type 2 diabetes Weight management Type 2 diabetes + weight management
Maximum dose 2 mg weekly 2.4 mg weekly 15 mg weekly
Average weight loss 10–15% 15–17% 18–22%
NHS availability Diabetes only Weight management services Diabetes + weight management

For a comprehensive side-by-side analysis, visit our UK weight loss injections comparison page.

Supply and availability in 2026

The UK experienced intermittent supply issues with Ozempic during 2023 and 2024, largely driven by unprecedented global demand. As of early 2026, supply has largely stabilised, although periodic shortages of specific pen strengths may still occur.

The MHRA and the Department of Health and Social Care continue to monitor supply chains. NHS England has issued guidance prioritising Ozempic supply for patients with type 2 diabetes over off-label weight management use.

If you are affected by a supply shortage, your pharmacist or prescriber may suggest an alternative GLP-1 receptor agonist or adjust your treatment plan temporarily.

Frequently asked questions

Can I get Ozempic for weight loss on the NHS?

Ozempic is not licensed for weight loss in the UK and is therefore not typically prescribed on the NHS solely for weight management. However, if you have type 2 diabetes, the weight loss that occurs during treatment is a recognised benefit. For weight management specifically, your clinician may consider Wegovy or Mounjaro.

How long does it take for Ozempic to work?

Most patients begin to notice improvements in blood sugar control within 1 to 2 weeks. Weight loss effects typically become apparent after 4 to 8 weeks, with the most significant results occurring during the first 6 months of treatment at the maintenance dose.

Can I drink alcohol while taking Ozempic?

There is no specific contraindication to moderate alcohol consumption while taking Ozempic. However, alcohol can affect blood sugar levels, particularly in people with diabetes, and may worsen gastrointestinal side effects such as nausea. It is advisable to discuss alcohol intake with your prescriber.

What happens if I miss a dose?

If you miss a dose and the next scheduled dose is more than 2 days away, take the missed dose as soon as possible. If the next dose is due within 2 days, skip the missed dose and continue with your regular schedule. Do not take a double dose to make up for a missed one.